Clinical Trial Update: Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers [Phase 3]

View source ↗

Summary

Extension Phase 3 trial evaluating the safety, tolerability, and immunogenicity of the Novartis meningococcal B recombinant vaccine when administered as a boost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal B Recombinant Vaccine (recombinant meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-03